The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Physical activity levels have a significant association with a reduced incidence of restrictive spirometry patterns (RSP).

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.